PNC-27

PNC-27 is a synthetic peptide combining a p53-derived sequence with a membrane-residing peptide segment. It was developed at New York Medical College and Albert Einstein College of Medicine as a proof-of-concept anticancer research peptide that selectively disrupts cancer cell membranes while sparing healthy cells. It is sold strictly for laboratory research and has not been approved for any clinical use.

PNC-27 is one of the more dramatic experimental cancer research peptides. It was designed to act like a guided missile aimed at cancer cells: the targeting end binds a protein (HDM-2) that's abnormally present on the membrane of many cancer cells, and the membrane-disrupting end then punches holes in those cells. Healthy cells, which don't display HDM-2 on their surface, are largely spared in laboratory studies.

PNC-27 binds HDM-2 expressed on the membrane of cancer cells and forms transmembrane pores that cause necrosis. Because healthy cells generally lack surface HDM-2, the disruption is theoretically selective. The mechanism is necrotic rather than apoptotic, which is unusual for an anticancer compound.

• •Pancreatic cancer cell lines
• •Leukemia and lymphoma research
• •Solid tumor models
• •Membrane-disrupting peptide pharmacology
• •Cancer cell selectivity studies

PNC-27 is discussed mainly in alternative cancer research and biohacker forums. The conversation is controversial — supporters cite preclinical selectivity data, while skeptics note the lack of major clinical advancement and the seriousness of self-experimenting with cancer research compounds.

“An experimental cancer-cell-popping research peptide.”

Not stacked in the conventional sense. Studied in isolation in oncology research.

PNC-27 is an experimental anticancer research peptide that disrupts cancer cell membranes by binding membrane HDM-2. It is preclinical, controversial, and sold strictly for laboratory research.